Table 4.
Recently whole-virus-based vaccine and viral vector-based vaccine candidates against SARS-CoV-2.
| Developer | Platform | Type of candidate vaccine | Current stage |
|---|---|---|---|
| Sinovac | Inactivated | Formaldehyde inactivated with alum | Pre-clinical |
| Codagenix/Serum Institute of India | Live attenuated virus | Deoptimized live attenuated vaccines | Pre-clinical |
| Codagenix/Serum Institute of India | Live attenuated virus | Deoptimized live attenuated vaccines | Pre-clinical |
| GeoVax/BravoVax | Non-replicating viral vector | MVA encoded VLP | Pre-clinical |
| Janssen Pharmaceutical Companies | Non-replicating viral vector | Ad26 (alone or with MVA boost) | Pre-clinical |
| University of Oxford | Non-replicating viral vector | ChAdOx1 | Pre-clinical |
| Altimmune | Non-replicating viral vector | Adenovirus-based NasoVAX | Pre-clinical |
| Greffex | Non-replicating viral vector | Ad5 S (GREVAX™ platform) | Pre-clinical |
| Vaxart | Non-replicating viral vector | Oral vaccine platform | Pre-clinical |
| CanSino Biologics | Non-replicating viral vector | Viral-vectored based | Pre-clinical |
| Zydus Cadila | Replicating viral vector | Measles vector | Pre-clinical |
| Institute Pasteur | Replicating viral vector | Measles vector | Pre-clinical |
| Tonix Pharma/Southern Research | Replicating viral vector | Horse-pox vector | Pre-clinical |